2nd edition .
This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. This Framework does not apply to seasonal influenza viruses or other non-influenza pathogens or biological substances that may be contained in clinical ...specimens shared under this Framework
This second edition of the Pandemic Influenza Preparedness (PIP) Framework reflects an amendment to Annex 2, Standard Material Transfer Agreement 2, Footnote 1, that was adopted by the Seventy-second World Health Assembly in May 2019.The amendment clarifies that, under certain circumstances, the indirect use of PIP Biological Materials will require the conclusion of an SMTA2. The amendment is in effect from the closure of the Seventy-second World Health Assembly (28 May 2019).
more
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...ed below.
This document has been updated: Version 15 March 2022.
more
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
more
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...is document has been updated: version 15 March 2022.
more
Laboratory Safety Handbook. Global edition
Las pruebas de cultivo y sensibilidad a fármacos son necesarias especialmente para los pacientes con riesgo de tuberculosis resistente a los medicamentos y para vigilar su respuesta al tratamiento. Si bien el cultivo y las pruebas de sensibilidad son ca...da vez más accesibles, la infraestructura para realizarlos es compleja y requiere equipos especializados y costosos. Con vistas a garantizar que el personal de laboratorio realice su trabajo de forma correcta y segura, este manual ofrece una guía práctica mediante textos sencillos e ilustraciones claras que ayudan a comprender los problemas de seguridad conexos. De ahí la importancia de su publicación en español para la red de laboratorios nacionales y supranacionales que apoya la Organización Panamericana de la Salud en la Región de las Américas.
more
The African Centers for Disease Control and Prevention and the African Union together have called for a New Public Health Order which will safeguard the health and economic security of the continent as it strives to meet the aspirations of the Agenda 2063. A key pillar of this mandate seeks to expan...d the local manufacture of vaccines, diagnostics, and therapeutics. Presently, less than one percent of vaccines administered on the continent are manufactured locally. This places a great burden on the health systems of African countries and reduces their ability to respond to pandemics and other health crises.
more
Estas directrices sustituyen a los anteriores documentos de política de la OMS sobre el manejo de la ILTB en las personas con la infección por el VIH, los contactos del hogar de personas con TB y otros grupos de riesgo. Las Directrices unificadas de la OMS sobre la tuberculosis: Tratamiento preven...tivo de la tuberculosis se elaboraron conforme a los requisitos del Comité de Examen de Directrices. El grupo de elaboración de las directrices (GDG, por su sigla en inglés) examinó la calidad de la evidencia más reciente disponible sobre la efectividad y los posibles perjuicios, así como la certeza de la evidencia, los valores y las preferencias, además de cuestiones de equidad, utilización de recursos, aceptabilidad y viabilidad de la aplicación al actualizar o formular nuevas recomendaciones y determinar su fuerza.
more
A framework to implement the Agenda for the Americas on Health, Environment, and Climate Change 2021–2030
This report, which involved input from across WaterAid, in particular from the Programme Support Unit (PSU) of WaterAid UK, includes case studies from a variety of countries, including Bangladesh, Burkina Faso, Eswatini, Ethiopia, Ghana, India and Nepal, each demonstrating what must be done now to i...mprove WASH services and address current challenges, in order to increase community resilience to climate change.
more
The WHO Global strategy on human resources for health: workforce 2030 encourages development partners and global health initiatives to leverage their support to health systems in countries to sustainably strengthen the health workforce. To assess the impact of these investments, a methodology was de...veloped and pilot tested by WHO.
The impact assessment tool (consisting of an MS Excel calculator with two subsets) supports users to:
• assess and quantify the health impact of HRH investments made in the context of HIV, tuberculosis (TB) and malaria programmes through their modelled effect on health service coverage of these three diseases; and
• provide aggregate indicative estimates of the range of health workers required to attain high coverage of selected health services.
more
Wearing a face mask can help reduce the spread of COVID-19 in the community by reducing the release of respiratory droplets from asymptomatic / pre-symptomatic individuals or those with mild non-specific symptoms. The use of face masks for this purpose may be adopted to reduce the societal impact as...sociated with absence from work or healthcare pressures due to infection, or to protect vulnerable individuals in particular settings.
more
The report notes that the number of people in need of one or more assistive products is likely to rise to 3.5 billion by 2050, due to populations ageing and the prevalence of noncommunicable diseases rising across the world. The report also highlights the vast gap in access between low- and high-inc...ome countries. An analysis of 35 countries reveals that access varies from 3% in poorer nations to 90% in wealthy countries.
Affordability is a major barrier to access, the report notes. Around two thirds of people with assistive products reported out-of-pocket payments for them. Others reported relying on family and friends to financially support their needs.
more